ImmunityBio, Inc. (IBRX)
Listed on NASDAQ • Healthcare / Biotechnology
Overview
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Explore More Data
Key Information
Symbol:
IBRX
CEO:
Richard Gerald Adcock
Exchange:
NASDAQ
CIK:
0001326110
Website:
https://immunitybio.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
2.15
Change
0.07
Change %
3.37%
Open
2.19
Previous Close
2.08
High
2.27
Low
2.07
Volume
13,168,485
Market Cap
2,117,675,264
EV/EBITDA
0
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
984,965,179
FloatShares
322,813,927
Float Ratio
32.77%
Shares Short
72,564,054
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
21.93%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
6.89 trading days
Held Percent Insiders
66.41%
Held Percent Institutions
12.81%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date (Estimated) | 2025-11-10 |
| Earnings Call (Estimated) | |
| Avg EPS Estimate | -0.11 |
| Low EPS Estimate | -0.14 |
| High EPS Estimate | -0.09 |
| Revenue | |
| Avg Revenue Forecast | 35,888,000 |
| Low Revenue Forecast | 30,000,000 |
| High Revenue Forecast | 47,640,000 |
IBRX Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $153,658,000 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 3.475 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 4.11 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $842,667,008 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
IBRX Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $-269,065,984 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-349,558,016 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-249,235,872 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 99.66% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -269.76% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 0.00% | Net profit margin, which reflects overall profitability. |
IBRX Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 0.00% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $842,667,008 | Used together with cash and EBITDA to assess debt-paying ability. |
IBRX Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 2423.90% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for IBRX (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $2.15 | Latest stock trading price |
| Price Target (High) | $24 | Analyst highest expected price |
| Price Target (Low) | $5 | Analyst lowest expected price |
| Price Target (Average) | $10.2 | Average target price across analysts |
| Price Target (Median) | $8 | Median of target prices |
| Average Rating Score | 0 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | none | Consensus rating |
| Analyst Coverage Count | 5 | Number of analysts providing estimates |
| Cash Holdings | $153,658,000 | Total cash held by the company |
| Cash per Share | $0.16 | Cash value per outstanding share |
| Total Debt | $842,667,008 | Company's total debt |
| Quick Ratio | 3.475 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 4.11 | Overall short-term liquidity |
| Debt/Equity Ratio | 0.00% | Leverage ratio: Debt / Equity |
| EBITDA | $-269,065,984 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $56,600,000 | Total company revenue |
| Revenue per Share | $0.071 | Total revenue divided by shares outstanding |
| Gross Profit | 99.66% | Revenue minus cost of goods sold |
| Return on Assets | -42.14% | Net income / Total assets |
| Return on Equity | 0.00% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 2423.90% | Year-over-year revenue growth |
| Gross Margin | 99.66% | Gross profit / Total revenue |
| EBITDA Margin | 0.00% | EBITDA / Revenue |
| Operating Margin | -269.76% | Operating income / Revenue |
| Profit Margin | 0.00% | Net income / Revenue |
| Free Cash Flow | $-249,235,872 | Cash left after capital expenditures |
| Operating Cash Flow | $-349,558,016 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |